DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/j4gkw7/sleep_disorder) has announced the addition of the "Sleep Disorder Treatment Drugs Markets in China" report to their offering.
China's demand for Sleep Disorder Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades.
This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2004, 2009 and 2014) and long-term forecasts through 2019 and 2024 are presented. Major producers in China are profiled.
Report Coverage
- Barbiturates
- Phenobarbital
- Secobarbital
- Amobarbital
- Benzodiazepines
- Midazolam
- Estazolam
- Triazolam
- Non-benzodiazepines
- Zolpidem
- Zopiclone
- Zaleplon
- Acanthopanacis Senticosi
- Gastrodin
Key Topics Covered:
I. INTRODUCTION
II. BUSINESS ENVIRONMENT
III. SLEEP DISORDER TREATMENT DRUGS INDUSTRY ASSESSMENTS
IV. SLEEP DISORDER TREATMENT DRUGS PRODUCTION AND DEMAND
V. SLEEP DISORDER TREATMENT DRUGS MARKET OUTLOOK
VI. MARKETING STRATEGIES
VII. SLEEP DISORDER TREATMENT DRUGS PRODUCER DIRECTORY
Companies Mentioned
- Wusuli River Pharmaceutical Group
- Wandashan Pharmaceutical Factory
For more information visit http://www.researchandmarkets.com/research/j4gkw7/sleep_disorder